The product - StablevaX™
Our C.S.O and founder Dr Bruce Roser MB BS, PhD, FRCPA identified and patented the process of using the sugar Trehalose to achieve a state of ‘suspended animation’ in a sugar glass to thermally stabilize many vaccines. Trehalose is a naturally occurring sugar with remarkable chemical stability that can stabilize delicate molecules against very hostile environments. This property is observed naturally in some living organisms, most notably in the case of the “resurrection” plant.
Stablepharma does not make or develop vaccines - we take existing WHO approved vaccines, reformulate and stabilise them, and deliver them in a unique way with our patented process.
Trehalose’s stabilising properties are already used in c. 25 approved pharmaceuticals worldwide. To date we have identified c. 60 vaccines suitable for our process . We are now using our technology StablevaX™ on the current Covid-19 mRNA vaccines. Once approved, this will have a huge impact on immunisation around the world.
The StablevaX™ product consists of a syringe containing a vaccine stabilised within a compressible matrix.
- Water is drawn into syringe prior to injection, this results in the release of vaccine from the compressible matrix
- Vaccine is then administered via compression of the compressible matrix by the plunger
StablevaX™ has been designed to meet the criteria for usage required by the World Health Organisation (WHO) and its use in the field requires little or no extra training.
Stablepharma does not make or develop new vaccines - we take existing vaccines and stabilize them in trehalose glass within the pores of a medical grade scompressible matrix, using the patented StablevaX™ technology. This compressible matrix is then housed in the barrel of a syringe, which acts both as storage and delivery vessel. By housing the pre-dosed and stable vaccine in a syringe, we ensure safe, efficient, and waste-free delivery without the need for a cold chain.
Technology has been tested with positive results
6 years of R&D work concluded with an independent study conducted by UK’s National Institute for Biological Standards and Control (NIBSC) confirmed that a StablevaX™ version of the Tetanus vaccine produced the same level of antibody response as the existing fresh vaccine produced by leading pharmaceutical companies.
Having achieved this milestone of successful testing in animals, we are now able to move forward to the next milestone of First in Human Clinical Trials.
StablevaX™ is a patented product that aims for enhanced thermostability, following the WHO protocols